Deferred Tax Assets Deferred Income Current Genzyme co-promotion agreement Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from current deferred income. Deferred Tax Assets Accruals Depreciation and Deferred Rent Current Accruals and deferred rent Represents the amount before allocation of valuation allowances of deferred tax asset attributable to current accruals, depreciation and deferred rent. Components of Deferred Tax Liabilities Current [Abstract] Deferred tax liabilities: Deferred Tax Assets Deferred Income Non Current Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-current deferred income. Genzyme co-promotion agreement Deferred Tax Assets Accruals Depreciation and Deferred Rent Non Current Accruals, depreciation and deferred rent Represents the amount before allocation of valuation allowances of deferred tax asset attributable to non-current accruals, depreciation and deferred rent. Components of Deferred Tax Liabilities Non Current [Abstract] Deferred tax liabilities: Components of Deferred Tax Assets Non Current [Abstract] Non-current deferred tax assets: Outside Director Serving as Member of Board of Directors for at Least Six Months [Member] Outside director serving as a member of Board of Directors for at least six months Represents information pertaining to outside director serving as a member of Board of Directors for at least six months. Share Based Compensation Arrangement by Share Based Payment Award Award Percentage Vesting on Monthly Basis Percentage of award granted which vests on a monthly basis Percentage of award granted which vests on a monthly basis. Share Based Compensation Arrangement by Share Based Payment Award Award Period Over which Vesting Will be on Monthly Basis Period over which remaining shares will vest on a monthly basis Represents the period over which grants of awards made will vest on a monthly basis. Amendment Description Share Based CompensationArrangementByShareBased Payment Award Period for Which Director Has to Serve as Board of Director to Receive Grant to Purchase Shares Period for which director has to serve as board of director to receive grant to purchase shares Represents the period for which director has to serve as board of director to receive grant to purchase shares. Amendment Flag Share Based Compensation Arrangement by Share Based Payment Award Award Expiration Period After Termination Expiration period after termination of service Expiration period of award after termination of service, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Professional licensure fees paid to TCP Professional Licensure Fees Cost of professional licensure fees directly related to generating revenues. Proceeds from Reimbursed Rent Reimbursed rent Proceeds from reimbursed rent and related operating costs for shared leased facilities. Tenant improvement allowances Tenant Improvement Allowance Amount of tenant improvement allowance granted by the lessor to a tenant under the terms of the agreement. Class of Warrant or Right Number of Securities for which Warrants Became Exercisable Number of shares for which warrant became exercisable Represents the number of securities for which warrants became exercisable. Common Stock Warrants [Member] Common Stock Warrants Shares of common stock issuable upon exercise of warrants Represents the security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Underwriting Discounts and Commissions Underwriting discounts and commissions Represents the amount of underwriting discounts and commissions payable by the entity. Class of Warrant or Right Number of Securities for which Warrants will Become Exercisable in Event of Conversion of Preferred Stock Into Common Stock Number of shares for which warrant became exercisable Represents the number of securities for which warrants will become exercisable in the event of conversion of outstanding convertible preferred stock into common stock. Preferred Stock Number of Series Number of series in which preferred stock may be issued. Number of series in which preferred stock may be issued Exercise Price Dollars 12.12 [Member] $12.12 Represents the exercise price of 12.12 dollars per share. Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block] Schedule of reserved shares of common stock for issuance Tabular disclosure of number of common shares reserved for future issuance. Voting Rights for Each Share of Stock Number of votes for each share of stock Represents the number of votes for each share of stock. Series A Convertible Preferred Stock [Member] Series A convertible preferred stock Represents information pertaining to the series A convertible preferred stock. Series A Series B Convertible Preferred Stock [Member] Series B convertible preferred stock Represents information pertaining to the series B convertible preferred stock. Series B Schedule of Activity of Allowance for Doubtful Accounts [Table Text Block] Schedule of activity of allowance for doubtful accounts Tabular disclosure of activity of allowance for doubtful accounts during the period. Schedule of Depreciation and Amortization Expense [Table Text Block] Schedule of depreciation and amortization expense recorded in the statements of operations and comprehensive loss Tabular disclosure of depreciation and amortization expense recorded in the statements of operations and comprehensive loss. Current Fiscal Year End Date Award Type [Axis] Stock Plan 2008 [Member] 2008 Plan Represents information pertaining to the 2008 Stock Plan (the 2008 Plan). 2013 Plan Represents information pertaining to the 2013 Stock Incentive Plan (the 2013 Plan). Stock Incentive Plan 2013 [Member] Share Based Compensation Arrangement by Share Based Payment Award Term of Options Granted to Employees Who Owned Specified Percentage of Class of Stock Term of options granted to a person owning stock representing more than 10% of voting power of all classes of stock Represents the term of options granted to persons owning stock representing specified percentage of voting power of all classes of stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share based Compensation Arrangement by Sharebased Payment Award Purchase Price of Stock Percentage for Grants to Persons Who Owned Specified Percentage of Class of Stock Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing more than 10% of voting power of all classes of stock Option price as a percentage of estimated fair value of shares on date of grant to a person owning stock representing specified percentage of voting power of all classes of stock. Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract] Weighted Average Remaining Contractual Life Excess Payment Related to Testing and Evaluation Services Excess payment included in accounts payable Represents the amount of excess payment related to testing and evaluation services included in accounts payable as of balance sheet date. Purchase Obligation [Abstract] Volume Purchase Agreement Employee and non Employee Stock Option [Member] Options An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement. Shares of common stock subject to outstanding options Research and development credit Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible research and development tax credit carryforwards. Deferred Tax Assets Tax Credit Carryforwards Research and Development Income Tax Examination Period Income tax examination period Period which will remain open for examination by tax authorities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Represents the period for which research tax credit is extended in respect of qualified research expenditures incurred through the end of specified period. Income Taxes Period for which Research Tax Credit Extended for Qualified Research Expenditures Incurred Through End of Specified Period Period for which research tax credit extended for qualified research expenditures incurred through the end of 2013 Document Period End Date $2.68 Represents the exercise price of 2.68 dollars per share. Exercise Price Dollars 2.68 [Member] Exercise Price Dollars 4.00 [Member] $4.00 Represents the exercise price of 4.00 dollars per share. Exercise Price Dollars 6.04 [Member] $6.04 Represents the exercise price of 6.04 dollars per share. Class of Warrant or Right Potential Number of Aggregate Securities Exercisable Aggregate number of shares for which warrant becomes exercisable if Company draws down second term loan (in shares) Number of securities into which each warrant or right may be become exercisable . For example, but not limited to, each warrant may be converted into two shares. Number of countries outside United States in which marketing authorization is obtained Represents the number of countries outside United States in which marketing authorization is obtained under the agreement. Collaborative Arrangement Number of Countries Outside United States in which Marketing Authorization is Obtained Additional payments that may be received Represents the additional payments that may be received under the agreement. Collaborative Arrangement Additional Payments That May Be Received Collaborative Arrangement Additional Payments that may be Received for Each Country Outside United States In which Entity Obtains Marketing Authorization and Achieves Specified Level of Reimbursement Additional payments that may be received for each country outside of the United States in which the company obtains marketing authorization and achieves a specified level of reimbursement Represents the additional payments that may be received for each country outside of the United States in which the entity obtains marketing authorization and achieves a specified level of reimbursement under the agreement. Number of countries outside United States for which additional payments may be received Represents the number of countries outside United States for which additional payments may be received under the agreement. Collaborative Arrangement Number of Countries Outside United States for which Additional Payments May be Received Collaborative Arrangement Percentage of Cash Receipts of Co-Promotion Fees for Remaining Periods Represents the percentage of cash receipts of co-promotion fees to be received by the co-promoter for the remaining periods under the agreement. Percentage of cash receipts of co-promotion fees received by co-promoter for remaining periods Entity [Domain] Collaborative Arrangement Maximum Amount to be Spent by CoPromoter for Qualifying Clinical Development Activities in Countries that Require Additional Testing for Approval Maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing Represents the maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing for approval under the agreement. Collaborative Arrangement Co Promotion Fee Amortization Period Amortization period of co-promotion fee Represents the amortization period of co-promotion fee. Represents the security that gives the holder the right to purchase shares of convertible preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Convertible Preferred Stock Warrants [Member] Convertible Preferred Stock Warrant Arrangements and Non-arrangement Transactions [Domain] Represents the percentage of likelihood that the second tranche of convertible preferred stock will succeed, used as an input to measure fair value. Fair Value Assumptions Probability of Success of Second Tranche of Convertible Preferred Stock Probability of success of the second tranche (as a percent) Number of installments Represents the number of installments for payment of the debt. Debt Instrument Number of Installments Debt Instrument Period after which Debt is Repayable Period after which debt is repayable Represents the period after the date of borrowing in which the debt is repayable under the agreement. Represents the percentage of prepayment penalties for prepayment within one year of the loan origination. Debt Instrument Penalty Percentage on Prepayment within One Year of Origination Prepayment penalties for prepayment within one year of the loan origination (as a percent) Debt Instrument Penalty Percentage on Prepayment within Two Years of Origination Prepayment penalties for prepayment within two years of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment within two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment after Two Years of Origination Prepayment penalties for prepayment after two years of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment after two years of the loan origination. Debt Instrument Remaining Discount Amortization Period Amortization period of debt discount Represents the remaining amortization period for discount on the debt. Accrued Consulting Fees Current Accrued consulting fees Carrying value, as of the balance sheet date, of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Series C Series C Convertible Preferred Stock [Member] Series C convertible preferred stock Represents information pertaining to the series C convertible preferred stock. Class of Warrant or Right Number of Securities for which Warrants may become Exercisable Remaining number of shares for which warrant may become exercisable Represents the number of securities for which warrants may become exercisable. Warrants and Rights Note Disclosure [Text Block] Convertible Preferred Stock Warrants Disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Represents term loan one of the reporting entity. Term Loan One [Member] Term loan Weighted Average Basic and Diluted Shares Outstanding Pro Forma Shares used in computing pro forma net loss per common share, basic and diluted Represents the weighted average number of shares (units) outstanding in the calculation of pro forma basic and diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering. Stock-based compensation The aggregate amount of noncash, equity-based employee remuneration for non-bonus related compensation. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Share Based Compensation Non Bonus Related Equity-based compensation The aggregate amount of noncash, equity-based employee remuneration for bonus related compensation. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Share Based Compensation Bonus Related Increase (Decrease) in Accrued Liabilities and Deferred Rent Accrued liabilities and deferred rent The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent. Thyroid Cytopathology Partners Stock-based Compensation An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation. Employee and Non Employee Stock Option Excluding Bonus Compensation [Member] An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as bonus related compensation. Employee Stock Option Bonus Compensation [Member] Equity-based Compensation Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties. Medicare Represents information pertaining to Medicare, a significant third-party payer. Medicare [Member] Aetna [Member] Aetna Represents information pertaining to Aetna, a significant third-party payer. United Healthcare [Member] United Healthcare Represents information pertaining to United Healthcare, a significant third-party payer. Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited Number of major financial institutions with which the company's cash and cash equivalents are deposited Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity. Allowance for Doubtful Accounts [Abstract] Allowance for Doubtful Accounts Temporary Equity Disclosure [Text Block] Convertible Preferred Stock Disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Temporary Equity Number of Shares that May be Sold in Additional Closings Number of shares that may be sold in additional closing Represents the number of shares that may be sold in additional closings under the agreement. Number of additional closings Represents the number of additional closings. Number of Additional Closings Temporary Equity Stock Issued During Period Shares Number of shares issued Represents the number of shares classified as temporary equity issued during the period. Expenses for cytopathology testing and evaluation services Testing and evaluation service costs directly related to generating revenues. Testing and Evaluation Services Expense Represents the amount of end of term payment of debt. Debt Instrument End of Term Payment Amount Amount of end of term payment Represents the end of term payment as a percentage of total outstanding principal balance of debt. Debt Instrument End of Term Payment as Percentage of Total Outstanding Principal End of term payment as a percentage of total outstanding principal balance Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward] Shares Available for Grant The weighted average grant-date fair value of options exercised during the reporting period. Share Based Compensation Arrangement by Share Based Payment Award Options Exercises in Period Weighted Average Grant Date Fair Value Weighted average fair value of stock options exercised (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Genzyme Co-promotion Agreement Genzyme Represents information pertaining to Genzyme Corporation, a co-promoter. Genzyme Corporation [Member] Document and Entity Information Represents the period of prior notice for termination of the agreement. Collaborative Arrangement Prior Notice Period for Termination of Agreement Prior notice period for termination of agreement Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation, employee An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation. Stock-based Compensation, employees and directors Non Employee Stock Option [Member] Stock-based Compensation, non-employees An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Entity Well-known Seasoned Issuer An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as annual bonus related compensation. Employee Stock Option Annual Bonus Compensation [Member] Equity-based Compensation, executive bonuses Entity Voluntary Filers Employee Stock Option Performance Bonus Compensation [Member] An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as bonus compensation related to specified performance. Equity-based Compensation, incentive stock options Entity Current Reporting Status Percentage of cash receipts of co-promotion fees received by co-promoter Represents the percentage of cash receipts of co-promotion fees received by the co-promoter under the agreement. Collaborative Arrangement Percentage of Cash Receipts of Co-Promotion Fees Entity Filer Category Exercise Price Dollars 0.08 [Member] $0.08 Represents the exercise price of 0.08 dollars per share. Entity Public Float Represents the exercise price of 0.80 dollars per share. Exercise Price Dollars 0.80 [Member] $0.80 Entity Registrant Name $2.36 Represents the exercise price of 2.36 dollars per share. Exercise Price Dollars 2.36 [Member] Entity Central Index Key Exercise Price Dollars 2.40 [Member] $2.40 Represents the exercise price of 2.40 dollars per share. Exercise Price Dollars 7.92 [Member] $7.92 Represents the exercise price of 7.92 dollars per share. Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period one. Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period One Percentage of co-promotion fee required to be repaid if agreement terminated prior to January 2014 Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period Two Percentage of co-promotion fee required to be repaid if agreement terminated between January 2014 and January 2015 Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period two. Entity Common Stock, Shares Outstanding Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period Three Percentage of co-promotion fee required to be repaid if agreement terminated between January 2015 and January 2016 Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period three. Organization and Summary of Significant Accounting Policies [Table] Disclosure for all significant accounting policies of the reporting entity. Organization and Summary of Significant Accounting Policies [Line Items] Overview Represents the amount of co-promotion expenses incurred under the agreement. Collaborative Arrangement Co Promotion Expenses Co-promotion expenses Collaborative Arrangement Outstanding Obligation Outstanding obligation to Genzyme Represents the amount of outstanding obligation under the agreement. Preferred stock warrants converted (in shares) Represents the number of shares of preferred stock warrants converted. Class of Warrant or Right Number of Shares of Preferred Stock Warrants Converted Class of Warrant or Right Shares of Common Stock Warrants Issued Upon Conversion of Shares of Preferred Stock Warrants Warrants issued to purchase common stock upon conversion of preferred stock warrants (in shares) Represents the number of shares of common stock warrants issued upon conversion of shares of preferred stock warrants. $0.08-$12.12 Represents the range of exercise prices from 0.08 dollars to 12.12 dollars per share. Exercise Price Range from Dollars 0.08 to Dollars 12.12 [Member] Value of convertible preferred stock issued during the period. Stock Issued During Period Value Convertible Preferred Stock Issuance of convertible preferred stock, net of issuance costs and preferred stock liability Stock Issued During Period Shares Convertible Preferred Stock Issuance of convertible preferred stock, net of issuance costs and preferred stock liability (in shares) Number of convertible preferred shares issued during the period. Adjustments to Additional Paid in Capital on Reclassification of Preferred Stock Warrant Reclassification of preferred stock warrant liability into additional paid-in capital upon initial public offering Amount of increase in additional paid-in capital (APIC) upon reclassification of preferred stock warrant liability during the period. Adjustments to Additional Paid in Capital Share Based Compensation Employee Stock-based compensation expense (employee) Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense. Stock-based compensation expense (non employee) Adjustments to Additional Paid in Capital Share Based Compensation Non Employee Amount of increase in additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense. Adjustments to Additional Paid in Capital Equity Based Compensation Equity-based compensation Represents the amount of increase in additional-paid in capital (APIC) resulting from equity-based compensation. Common stock subject to repurchase Represents the amount of decrease in additional paid-in capital (APIC) due to common stock subject to repurchase. Adjustments to Additional Paid in Capital Common Stock Subject to Repurchase Convertible Preferred Stock Issued Issuance Costs Issuance of convertible preferred stock, issuance cost Direct costs (e.g., legal and accounting fees) associated with issuing convertible preferred stock. Also includes any direct costs associated with stock issues under a shelf registration. Conversion of Preferred Stock Warrant Liability Amount Converted Conversion of preferred stock warrant liability to common stock warrants The value of the preferred stock warrant liability converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. Document Fiscal Year Focus Common Stock Issued Issuance Costs Issuance of common stock in initial public offering, issuance cost Document Fiscal Period Focus Future cash outflow to pay for convertible preferred stock issuance costs. Preferred Stock Issuance Costs Incurred but Not Yet Paid Convertible preferred stock issuance costs included in accounts payable Stock Based Compensation Transfer to Equity Transfer of equity-based compensation from liabilities to equity Represents the amount of equity based compensation transferred from liabilities to equity. Net Proceeds from Issuance of Redeemable Convertible Preferred Stock Proceeds Net of Issuance Costs and Preferred Stock Liability Represents the cash inflow from proceeds net of issuance costs and preferred stock liability. Number of Closings Number of closings Represents the number of closings. Temporary Equity Number of Shares that May be Sold in Initial Purchase Number of shares that may be sold in initial purchase Represents the number of shares that may be sold in initial purchase under the agreement. Temporary Equity Number of Shares that May be Sold in Second Closing Number of shares that may be sold in second closing Represents the number of shares that may be sold in second closing under the agreement. Increase (Decrease) in Convertible Preferred Stock and Stockholders Equity [Roll Forward] Increase (Decrease) in Convertible Preferred Stock and Stockholders' Equity (Deficit) A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Issuance of convertible preferred stock, issue price (in dollars per share) Convertible Preferred Stock Original Issue Price Original Issue Price (in dollars per share) Original issue price of a single share of convertible preferred stock of a company. Preferred stock liability Fair Value of Preferred Stock Liability The fair value of preferred stock liability assumed in noncash investing or financing activities. Issuance of convertible preferred stock, preferred stock liability Derivative Financial Instruments Liabilities Preferred Stock Liability [Member] Preferred stock liability This item represents preferred stock liability derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect. Derivative Financial Instruments Liabilities Preferred Stock Warrant Liability [Member] Preferred stock warrant liability This item represents preferred stock warrant liability derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect. Legal Entity [Axis] Collaborative Arrangement Payment Received Amount received from Genzyme in connection with an extension of an exclusive right to negotiate co-promotion agreement Cash inflow from the extension of an exclusive right to negotiate agreement. Document Type The number of shares authorized to be issued and sold under the agreement entered into by the entity. Temporary Equity Stock Authorized to be Issued and Sold Shares authorized to be issued and sold Summary of Significant Accounting Policies Conversion of convertible preferred stock (in shares) Aggregate number of common shares to be issued in the conversion of convertible preferred stock. Conversion of Stock Shares Issued as If Converted Conversion of Stock Shares Issued as If Converted Convertible Preferred Stock Reserved for Issuance Conversion of convertible preferred stock reserved for issuance (in shares) Aggregate number of common shares reserved for future issuance for shares to be issued in the conversion of convertible preferred stock reserved for issuance. Employee Newly Hired [Member] Newly hired employee A newly hired employee. Share Based Compensation Arrangement by Share Based Payment Award Percentage of Voting Power of All Classes of Stock Voting power of person owning stock (as a percent) Voting power of all classes of stock, as a percent, of person owning stock as threshold for option terms under the entity's stock option plan. Share based Compensation Arrangement by Sharebased Payment Award Award Vesting Rights Percentage Year One Percentage of award vesting after one year Percentage of vesting of share-based compensation awards after one year from date of grant. Represents the amount of preferred stock liability transferred to equity. Transfer of Preferred Stock Liability to Equity Transfer of preferred stock liability to equity Fair Value of Preferred Stock Warrants Preferred stock warrants Represents the fair value of preferred stock warrants in noncash investing or financing activities. Incentive Stock Options [Member] ISO Represents information pertaining to incentive stock options (ISOs). Represents information pertaining to non statutory stock options (NSOs). Non Statutory Stock Options [Member] NSO Outside Director who was not Previously Employee [Member] Outside director who was not previously an employee Represents information pertaining to outside director, who was not previously an employee. Common Stock Discount on Shares and Commissions Issuance of common stock in initial public offering, discounts and commissions Amount of discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require and commissions on issuance of stock in initial public offering. Accounts payable Accounts Payable [Member] Fair Value Net Derivative Asset Liability Measured on Recurring Basis Unobservable Inputs Reconciliation Conversion Conversion of preferred stock warrant liability Amount of conversion of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Class of Warrant or Right Term of Warrants or Rights Warrant term Period over which each class of warrants or rights outstanding may be exercised. Outside Director [Member] Outside director Nonemployee serving on the board of directors (who collectively have responsibility for governing the entity). Share Based Compensation Arrangement by Share Based Payment Award Options Initial Grants Shares granted as initial grant Gross number of share options (or share units) granted to each individual as an initial grant. Share Based Compensation Arrangement by Share Based Payment Award Options Annual Grants Shares granted as annual grant Gross number of share options (or share units) granted to each individual as an annual grant. Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Extinguishment of Preferred Stock Liability Extinguishment of the preferred stock liability Represents the amount of extinguishment of the preferred stock liability. Proceeds from Issuance Initial Public Offering Net Net proceeds from issuance of common stock in IPO The net cash amount received from entity's first offering of stock to the public. Offering Expenses Offering expenses Amount of offering expenses payable by the entity. Organization Consolidation and Presentation of Financial Statements [Table] Disclosure of information about organization, consolidation and presentation of financial statements. Organization Consolidation and Presentation of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements Line Items Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Number of additional shares reserved for issuance Aggregate number of additional common shares reserved for future issuance under the plan. Common Stock Capital Additional Shares Reserved for Future Issuance Components Of Deferred Tax Assets Current [Abstract] Current deferred tax assets: Initial Public Offering Costs Included in Accounts Payable and Accrued Liabilities IPO costs included in accounts payable and accrued liabilities Represents the amount of IPO costs included in accounts payable and accrued liabilities. Accounts Receivable, Net, Current Accounts receivable, net of allowance of $107 and $222 as of December 31, 2013 and 2012 Accounts payable Accounts Payable, Current Outstanding obligations Accounts receivable Accounts Receivable [Member] Accrued Liabilities Accrued Liabilities, Current [Abstract] Accrued liabilities Accrued Liabilities [Member] Accrued Genzyme co-promotion fees Accrued Marketing Costs, Current Total accrued liabilities Accrued Liabilities, Current Accrued liabilities Accrued liabilities associated with employee and executive bonus plans Accrued Bonuses, Current Accrued legal and professional fees Accrued Professional Fees, Current Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense (in dollars) Allocated Share-based Compensation Expense Accounts receivable, allowance (in dollars) Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts Beginning balance Ending balance Activity of allowance for doubtful accounts Allowance for Doubtful Accounts Receivable [Roll Forward] Write-offs, net of recoveries Allowance for Doubtful Accounts Receivable, Write-offs Amortization of debt discount and issuance costs Amortization of Financing Costs and Discounts Amortization of debt discount and accretion Antidilutive Securities [Axis] Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Total shares of common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Long-lived Assets Asset Impairment Charges [Abstract] Total assets Assets Assets, Current [Abstract] Current assets: Assets [Abstract] Assets Assets, Current Total current assets Financial Assets Assets, Fair Value Disclosure Balance Sheet Location [Axis] Balance Sheet Components Balance Sheet Location [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Organization and Description of Business Business Description and Basis of Presentation [Text Block] Purchases of property and equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Amortization expense Capitalized Computer Software, Amortization Capitalized costs Capitalized Computer Software, Additions Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Chief Executive Officer Chief Executive Officer [Member] Common Stock Class of Stock [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Common stock warrants issued and outstanding (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrant to purchase shares of Series C convertible preferred stock (in dollars per share) Exercise price of warrants in the event of conversion of outstanding Series C convertible preferred stock into common stock (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Number of shares of preferred stock that can be purchased by each warrant Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Convertible preferred stock warrant Class of Warrant or Right [Line Items] Class of Stock [Domain] Class of Warrant or Right [Table] Variable Interest Entity, Classification [Domain] Genzyme Co-promotion Agreement Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement, Co-promotion [Member] Co-promotion agreement Genzyme Co-promotion Agreement Collaborative Arrangement Disclosure [Text Block] Commitments and Contingencies Commitments and contingencies (Note 8) Commitments and Contingencies. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Par value of shares of common stock (in dollars per share) Common Stock Common Stock [Member] Common stock Common stock, $0.001 par value; 125,000,000 and 77,000,000 shares authorized, 21,143,313 and 667,684 shares issued and outstanding as of December 31, 2013 and 2012 Common Stock, Value, Issued Common stock, shares issued Common Stock, Shares, Issued Issuance of common stock (in shares) Common stock, shares authorized Common Stock, Shares Authorized Authorized shares of common stock Shares of common stock reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Number of shares reserved for issuance Common stock, shares outstanding Common Stock, Shares, Outstanding 401(k) Plan Compensation Related Costs, Policy [Policy Text Block] Bonus Accruals Tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets Components of Deferred Tax Assets and Liabilities [Abstract] Computer equipment Computer Equipment [Member] Concentration Risk Type [Domain] Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Type [Axis] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentrations of credit risk (as a percent) Concentration Risk, Percentage Construction-in-process Construction in Progress [Member] Conversion of preferred stock into common stock upon initial public offering Conversion of Stock, Amount Converted Conversion of convertible preferred stock to common stock Convertible preferred stock converted to common stock (in shares) Conversion of Stock, Shares Converted Conversion of preferred stock into common stock upon initial public offering (in shares) Shares of common stock issuable upon conversion of preferred stock Convertible Preferred Stock [Member] Convertible Preferred Stock Common stock issued upon conversion of each preferred stock (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Cost of Revenue Cost of Sales, Policy [Policy Text Block] Cost of revenue Cost of Revenue Cost of revenue Cost of Sales [Member] Gross receivables concentration risk Credit Concentration Risk [Member] Revenue concentration risk Customer Concentration Risk [Member] Debt Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Face Amount Amount drawn down Amount drawn down of term loan Debt Debt Debt Disclosure [Text Block] Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Borrowing capacity available for second term loan Debt Instrument, Unused Borrowing Capacity, Amount Gross deferred tax liabilities Deferred Tax Liabilities, Gross, Noncurrent Schedule of unamortized balance of the co-promotion fee reflected in the Company's balance sheet Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Total deferred tax assets Deferred Tax Assets, Net Deferred rent, net of current portion Deferred Rent Credit, Noncurrent Deferred Revenue [Abstract] Unamortized balance of the co-promotion fee Gross deferred tax assets Deferred Tax Assets, Gross, Current Unamortized balance of the co-promotion fee Deferred Revenue Total Net non-current deferred tax liabilities Deferred Tax Assets, Net, Noncurrent Net current deferred tax assets (liabilities) Deferred Tax Assets, Net, Current Deferred Genzyme co-promotion fee Deferred Revenue, Current Deferred Genzyme co-promotion fee, net of current portion Deferred Revenue, Noncurrent Deferred rent-short-term Deferred Rent Credit, Current Gross deferred tax assets Deferred Tax Assets, Gross, Noncurrent Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Net current deferred tax liabilities Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Valuation allowance Deferred Tax Assets, Valuation Allowance, Current Valuation allowance Deferred Tax Assets, Valuation Allowance, Noncurrent Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Employer contributions to the plan Defined Contribution Plan, Cost Recognized Depreciation and amortization Depreciation, Depletion and Amortization Depreciation and amortization expense Aggregate fair value of the warrant for the shares exercisable under the warrant Fair value of currently exercisable portion of the warrant Preferred stock liability Derivative Liability, Current Fair value of liability Stock Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans Dividends Payable Dividends declared Outstanding obligations Due to Related Parties, Current Pro forma net loss: Earnings Per Share, Pro Forma [Abstract] Calculation of basic and diluted net loss per common share Earnings Per Share, Basic and Diluted [Abstract] Net loss per common share, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Net loss per common share, basic and diluted Net Loss Per Common Share Earnings Per Share [Text Block] Net Loss per Common Share Earnings Per Share, Policy [Policy Text Block] Net Loss Per Common Share Accrued compensation expenses (in dollars) Employee-related Liabilities, Current Anticipated grants accrual Stock-based compensation Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee stock options Employee Stock Option [Member] ISO Period over which unrecognized compensation expense expected to be recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Bonus Accruals Employee-related Liabilities, Current [Abstract] Laboratory equipment Equipment [Member] Stockholders' Equity (Deficit) Equity Component [Domain] Total Estimate of Fair Value Measurement [Member] Cumulative excess tax benefits from stock option deduction Excess Tax Benefit from Share-based Compensation, Operating Activities Measurement Frequency [Axis] Expected volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Change in value of preferred stock liability Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss) Preferred stock liability valuation decrease recorded in other income (expense), net Preferred stock liability settled Settlement of preferred stock liability Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements Beginning balance Ending balance Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Fair Value Measurements, Recurring and Nonrecurring [Table] Changes in the fair value of the Company's Level 3 financial liabilities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Hierarchy [Axis] Liability Class [Axis] Fair value measurements Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Recurring Fair Value, Measurements, Recurring [Member] Change in fair value of preferred stock liability recorded as other expense, net Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair value of liability Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues Fair Value, Measurement Frequency [Domain] Risk-free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Asset Class [Axis] Change in value of preferred stock warrant liability Fair Value Adjustment of Warrants Change in fair value of preferred stock warrant liability recorded in other income (expense), net Amount of change in the fair value reported as an expense in other income (expense), net Fair Value by Liability Class [Domain] Contractual term Fair Value Assumptions, Expected Term Term Assumptions used to calculate fair value of liability using the option-pricing method Assumptions used to calculate fair value of warrant upon issuance using Black-Scholes option-pricing valuation model Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Assumptions used to calculate fair value of preferred stock liability using the option-pricing method Fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Expected dividend yield (as a percent) Fair Value Assumptions, Expected Dividend Rate Fair Value Measurements Fair Value Hierarchy [Domain] Asset Class [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Assets Acquired Non-cash purchases of property and equipment Fair Value Measurements Fair Value Disclosures [Text Block] Summary of the changes in the fair value of the Company's Level 3 financial liabilities, which are measured on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Level III Fair Value, Inputs, Level 3 [Member] Level 3 Fair value measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Level I Fair Value, Inputs, Level 1 [Member] Level II Fair Value, Inputs, Level 2 [Member] Furniture and fixtures Furniture and Fixtures [Member] General and administrative General and Administrative Expense General and administrative General and Administrative Expense [Member] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Axis] Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairments Loss on write-off of property and equipment Impairment of Long-Lived Assets Held-for-use Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Pretax loss Statements of Operations and Comprehensive Loss Income Statement Location [Axis] Income Taxes Income Tax Authority [Domain] Income Tax Authority [Axis] Income Tax Disclosure [Text Block] Income Taxes Income Statement Location [Domain] Total Income Tax Expense (Benefit) Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Income tax examination Income Tax Examination [Line Items] Reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense Effective Income Tax Rate Reconciliation, Amount [Abstract] Income Tax Examination [Table] Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Permanent differences Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount U.S. federal taxes at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Income Taxes Income Tax, Policy [Policy Text Block] State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Increase (Decrease) in Accounts Payable Other assets Increase (Decrease) in Other Noncurrent Assets Co-promotion fee received from Genzyme Deferred Genzyme co-promotion fee Increase (Decrease) in Deferred Revenue Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Supplies inventory Increase (Decrease) in Inventories Prepaid expenses and current other assets Increase (Decrease) in Prepaid Expense and Other Assets Change in restricted cash Increase (Decrease) in Restricted Cash Nominal interest on the debt excluding amortization of debt discount and accretion Interest Expense, Debt, Excluding Amortization Interest expense Interest Expense Interest on debt balloon payment Interest Expense, Debt Interest on the debt Cash paid for interest on debt Interest Paid Internal-use Software Internal Use Software, Policy [Policy Text Block] Federal Internal Revenue Service (IRS) [Member] Inventory, Net Supplies inventory Supplies Inventory Inventory Supplies, Policy [Policy Text Block] Interest income Investment Income, Interest Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Reduction to rent expense for TCP's portion of costs for shared space Operating Leases, Rent Expense Leasehold improvements Leasehold Improvements [Member] Total current liabilities Liabilities, Current Total liabilities, convertible preferred stock, and stockholders' equity (deficit) Liabilities and Equity Current liabilities: Liabilities, Current [Abstract] Total liabilities Liabilities Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit) Liabilities and Equity [Abstract] Financial Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Fair value of liability Reimbursement for licensure fees License Costs Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit [Member] Loan and security agreement Thyroid Cytopathology Partners Long-term Contracts or Programs Disclosure [Text Block] Long-term debt, net of current portion Long-term Debt, Excluding Current Maturities Maximum Maximum [Member] Minimum Minimum [Member] Money market funds Money Market Funds [Member] Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net increase in cash and cash equivalents Net Cash Provided by (Used in) Continuing Operations Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss used in computing pro forma net loss per common share, basic and diluted Net loss and comprehensive loss Net loss attributable to common stockholders Net loss and comprehensive loss Generated a pretax loss Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net Income (Loss) Attributable to Parent Net loss Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Number of operating segments Number of Operating Segments Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating expenses: Operating Expenses [Abstract] 2017 Operating Leases, Future Minimum Payments, Due in Four Years Total operating expenses Operating Expenses 2018 Operating Leases, Future Minimum Payments, Due in Five Years 2016 Operating Leases, Future Minimum Payments, Due in Three Years Facilities rent expense Operating Leases, Rent Expense, Net 2014 Operating Leases, Future Minimum Payments Due, Next Twelve Months Loss from operations Operating Income (Loss) Operating Loss Carryforwards [Table] Operating loss carryforwards Operating Loss Carryforwards [Line Items] 2015 Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases Operating Leased Assets [Line Items] Total minimum lease payments Operating Leases, Future Minimum Payments Due Net operating loss carryforwards Operating Loss Carryforwards Organization and Description of Business Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Other assets Other Assets, Noncurrent Other income (expense), net Other Nonoperating Income (Expense) Accrued other Other Accrued Liabilities, Current Accrued Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Commissions and issuance costs relating to the initial public offering Payments of Stock Issuance Costs 401(k) Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Plan Name [Domain] Plan Name [Axis] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Issuance of convertible preferred stock, issue price (in dollars per share) Preferred stock, $0.001 par value; 5,000,000 and 0 shares authorized, 0 shares issued and outstanding as of December 31, 2013 and 2012 Preferred Stock, Value, Issued Preferred stock, shares issued Preferred Stock, Shares Issued Number of shares of preferred stock authorized Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Reverse Stock Split and Initial Public Offering Proceeds from Issuance or Sale of Equity [Abstract] Proceeds from the issuance of long-term debt, net of debt issuance costs Proceeds from Issuance of Long-term Debt Proceeds from Issuance Initial Public Offering Net proceeds from issuance of common stock in IPO Proceeds from issuance of common stock in initial public offering, gross Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds from Issuance of Redeemable Convertible Preferred Stock Gross proceeds from issuance of shares Proceeds from the exercise of common stock options Proceeds from Stock Options Exercised Estimated useful life Property, Plant and Equipment, Useful Life Total property and equipment, at cost Property, Plant and Equipment, Gross Total cost Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Net book value Total property and equipment, net Schedule of Property and equipment Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Axis] Property and Equipment, Net Property, Plant and Equipment [Line Items] Property and Equipment and Internal-use Software Bad debt expense Provision for Doubtful Accounts Charged to expense Estimated amount payable in 2014 Purchase Obligation, Due in Next Twelve Months Non-cancelable purchase obligations to contract manufacturers and suppliers Purchase Obligation Estimated amount payable in 2015 Purchase Obligation, Due in Second Year Selected Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Selected Quarterly Financial Data (Unaudited) Range [Axis] Range [Domain] Allowance for Doubtful Accounts Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Genzyme co-promotion fee amortization Amortization of up-front co-promotion fee Recognition of Deferred Revenue Reconciliation of the beginning and ending amount of unrecognized tax benefits Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Related Party [Axis] Related Party [Domain] Research and development Research and Development Expense Research and development Research and Development Expense [Member] Research and Development Research and Development Expense, Policy [Policy Text Block] Deposits Restricted Cash and Cash Equivalents Restricted Cash Restricted Cash and Investments [Abstract] Restricted Cash and Cash Equivalents, Current Restricted cash Certificate of deposit Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Letter of credit serving as security for lease Accumulated Deficit Retained Earnings [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Total estimated grant date fair value of options to purchase common stock vested (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Options exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options Vested and Exercisable, Aggregate Intrinsic Value (in dollars) Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Options Vested and Exercisable, Weighted Average Remaining Contractual Life Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price (in dollars per share) Exercise price of options granted expressed as a percentage of its fair value Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Term of options granted Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Fair value of fully vested stock options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Weighted average fair value of options to purchase common stock vested (in dollars per share) Fair value (in dollars per share) Options vested and expected to vest at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contractual term Options exercisable at the end of the period Balances at the beginning of the period Balances at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options Outstanding, Weighted Average Remaining Contractual Life Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Total revenues Revenue, Net Revenue Revenue Sales Revenue, Net [Member] Forecast Scenario, Forecast [Member] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of the fair value of the Company's financial assets and liabilities measured on a recurring basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Summary of activity under the Company's stock option plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions used to calculate the fair value of share based payments for option granted to employees and directors estimated on the date of grant using the Black Scholes option pricing valuation model Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation of tax expense computed at the statutory federal rate and the Company's tax expense Schedule of tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases Schedule of selected quarterly financial data (unaudited) Schedule of Quarterly Financial Information [Table Text Block] Schedule of the calculation of basic and diluted net loss per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Operating Leased Assets [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Summary of share-based compensation expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Property, Plant and Equipment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Stock by Class [Table] Summary of outstanding and exercisable stock options Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Schedule of Variable Interest Entities [Table] Schedule of the Company's significant third-party payers and their related revenue as a percentage of total revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Cash security deposit Security Deposit Selected Quarterly Financial Information [Abstract] Selected Quarterly Financial Data (Unaudited) Selling and marketing Selling and Marketing Expense Selling and marketing Selling and Marketing Expense [Member] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price (in dollars per share) Option exercise strike price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in dollars per share) Expected volatility, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Additional options authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, high end of range (as a percent) Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Maximum annual increase in outstanding shares on the last day of the immediately preceding fiscal year (as a percent) Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted (in shares) Stock incentive plans Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Preferred stock value (in dollars per share) Share Price Fair value of preferred stock (in dollars per share) Fair market value of common stock (in dollars per share) Issuance price per share in IPO (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, low end of range (as a percent) Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Canceled (in shares) Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Additions disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Balances at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Balances at the beginning of the period (in shares) Options available for grant under stock option plans (in shares) Number of shares available for issuance Intrinsic value of stock options exercised (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average fair value of options to purchase common stock granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Balances at beginning of the period (in dollars per share) Balances at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Balances at beginning of the period (in shares) Balances at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options issued and outstanding (in shares) Outstanding and exercisable stock options Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Options vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balances at the beginning of the period (in dollars) Balances at the end of the period (in dollars) Options Outstanding, Aggregate Intrinsic Value (in dollars) Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Stock Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Equity Award [Domain] Exercise price, low end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Options vested and expected to vest at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options Outstanding, Number of Options Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Options Vested and Exercisable, Number of Options Exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price, high end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Balance (in shares) Balance (in shares) Shares, Outstanding Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Capitalized software Software Development [Member] Software, including software developed for internal use Software and Software Development Costs [Member] State State and Local Jurisdiction [Member] Statement [Table] Statement Statement [Line Items] Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements of Cash Flows Equity Components [Axis] Balance Sheets Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock on exercise of stock options Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock into common stock upon initial public offering Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock on exercise of stock options (in shares) Number of shares issued and sold in IPO Stock Issued During Period, Shares, New Issues Issuance of common stock in initial public offering, net of discounts and commissions of $4,642 and issuance costs of $2,507 (in shares) Common stock issued on automatic conversion of outstanding convertible preferred stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock into common stock upon initial public offering (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in initial public offering, net of discounts and commissions of $4,642 and issuance costs of $2,507 Stockholders' deficit: Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity, Period Increase (Decrease) Balance Total stockholders' equity (deficit) Stockholders' Equity Attributable to Parent Balance Stockholders' Equity (Deficit) Stockholders' Equity Note Disclosure [Text Block] Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Subsequent Events Subsequent Events [Text Block] Subsequent Events Subsequent Event [Table] Subsequent Events Subsequent Event [Line Items] Subsequent Events Subsequent Event [Member] Subsequent events Subsequent Event Type [Domain] Subsequent Event Type [Axis] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Supplementary cash flow information of non cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Credit carryforwards available to reduce future taxable income Tax Credit Carryforward, Amount Credit carryforwards Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Table] Convertible preferred stock, shares outstanding Temporary Equity, Shares Outstanding Shares Outstanding Balance (in shares) Balance (in shares) Convertible preferred stock, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Convertible preferred stock, $0.001 par value; 0 and 59,147,999 shares authorized, 0 and 53,084,507 shares issued and outstanding as of December 31, 2013 and December 31, 2012; aggregate liquidation value of $0 and $65,835 as of December 31, 2013 and 2012 Temporary Equity, Carrying Amount, Attributable to Parent Balance Balance Schedule of convertible preferred stock Temporary Equity [Table Text Block] Convertible preferred stock Temporary Equity [Line Items] Convertible preferred stock, shares authorized Temporary Equity, Shares Authorized Number of authorized shares Shares Authorized Convertible Preferred Stock Convertible preferred stock, shares issued Temporary Equity, Shares Issued Shares Issued Aggregate liquidation value Temporary Equity, Liquidation Preference Aggregate Liquidation Amount Temporary Equity, by Class of Stock [Table] Temporary Equity, Carrying Amount, Period Increase (Decrease) Title of Individual [Axis] Relationship to Entity [Domain] Type of Arrangement and Non-arrangement Transactions [Axis] Interest expense or penalties related to unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Gross increases-current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Gross decrease-tax position in prior period Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized tax benefits, which if recognized, would affect the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized tax benefit Unrecognized Tax Benefits Unrecognized tax benefits, beginning of period Unrecognized tax benefits, end of period Gross increases-tax position in prior period Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Use of Estimates, Policy [Policy Text Block] Use of Estimates Increase in valuation allowance against deferred tax assets Valuation Allowance, Deferred Tax Asset, Change in Amount Variable Interest Entities [Axis] Thyroid Cytopathology Partners Variable Interest Entity, Not Primary Beneficiary [Member] Thyroid Cytopathology Partners Variable Interest Entity [Line Items] Warrant [Member] Shares of common stock warrants Convertible Preferred Stock Warrants Pro forma adjustments to reflect assumed conversion of convertible preferred stock (in shares) Weighted Average Number Basic Shares Outstanding Adjustment, Pro Forma Weighted Average Number of Shares Outstanding, Basic and Diluted Shares used to compute net loss per common share, basic and diluted (in shares) Shares used in calculation of net loss per share, basic and diluted Stock Issued During Period Shares Warrants Exercised Issuance of common stock on exercise of warrant (in shares) Number of shares of stock issued during the period as a result of the exercise of warrants.